EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis

Daisuke Ito iD, Kensuke Okada

Annals of Clinical and Translational Neurology · 2024-12 · 11 (12) · 3054-3063

DOI: 10.1002/acn3.52234 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 29.10.2024. Verfasst von Daisuke Ito und 1 weiteren Autor:innen. Beteiligte Einrichtung: Memory Center, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Oligonucleotides, Antisense. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antisense oligonucleotides, which are used to silence target genes, are gaining attention as a novel drug discovery modality for proteinopathies. However, while clinical trials for neurodegenerative diseases like amyotrophic lateral sclerosis have been conducted in recent years, the results have not always been favorable. The results from a Phase III trial of the antisense oligonucleotide, that is, tofersen, which targets SOD1 mRNA, showed decreased levels of cerebrospinal fluid SOD1 and plasma neurofilament light chain but no improvements in primary clinical endpoint. Moreover, case reports pertaining to patients with amyotrophic lateral sclerosis carrying FUS and C9orf72 mutations who received antisense oligonucleotide‐based treatments have demonstrated a notable reduction in the targeted protein (thus providing the proof of mechanism) but with no discernible clinical benefits. There are several possible reasons why antisense oligonucleotides knockdown fails to achieve proof of concept, which need to be addressed: on‐target adverse effects resulting from the loss of function of target gene and irreversible neuronal death cascade due to toxic protein accumulation, among other factors. This review provides an overview of the current status and discusses the prospects of antisense oligonucleotides treatment for amyotrophic lateral sclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisOligonucleotides, AntisenseAnimalsHumansSuperoxide Dismutase-1

Substanzen

Oligonucleotides, AntisenseSuperoxide Dismutase-1

Autor:innen und Institutionen

  • Memory Center, Keio University School of Medicine, Tokyo, Japan.
  • Department of Neurology, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Daisuke Ito

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology of Japan

Zitieren

APA

Ito, D., & Okada, K. (2024). Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 11(12), 3054-3063. https://doi.org/10.1002/acn3.52234

Vancouver

Ito D, Okada K. Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. 2024;11(12):3054-3063. doi:10.1002/acn3.52234

BibTeX
@article{Ito2024,
  author = {Ito, Daisuke and Okada, Kensuke},
  title = {Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  volume = {11},
  number = {12},
  pages = {3054--3063},
  doi = {10.1002/acn3.52234}
}
Kostenlos starten →